| Identification | More | [Name]
Ranolazine dihydrochloride | [CAS]
95635-56-6 | [Synonyms]
(+/-)-4-[2-HYDROXY-3-(O-METHOXYPHENOXY)PROPYL]-1-PIPERAZINEACETO-2',6'-XYLIDIDE DIHYDROCHLORIDE
n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide dihydrochloride
(+/-)-N-(2,6-DIMETHYLPHENYL)-4-[2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL]-1-PIPERAZINEACETAMIDE DIHYDROCHLORIDE
RANOLAZINE DIHYDROCHLORIDE
RANOLAZINE HCL
Ranolazine DiHCI
Ranolazine and salt
(±)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide
RANOLAZINE DI HCL
Ranolazine2Hcl
N-(2,6-Dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide dihydrochloride
Ranolazine Dihydrocloride
N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide Dihydrochloride
RS 43285
RS 43285-193
(±)-4-[2-Hydroxy-3-(o-methoxyphenoxy)propyl]-1-piperazineaceto-2μ,6μ-xylidide dihydrochloride, N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide dihydrochloride | [Molecular Formula]
C24H35Cl2N3O4 | [MDL Number]
MFCD03788770 | [Molecular Weight]
500.46 | [MOL File]
95635-56-6.mol |
| Chemical Properties | Back Directory | [Appearance]
White Crystalline Powder | [Melting point ]
222-229.5 °C(lit.) | [storage temp. ]
Desiccate at RT | [solubility ]
H2O: 10 mg/mL, soluble
| [form ]
solid
| [color ]
off-white
| [Water Solubility ]
H2O: soluble ≥10mg/mL | [Usage]
Anti-ischemic agent which modulates myocardial metabolism. Antianginal | [Merck ]
14,8111 | [Stability:]
Hygroscopic | [CAS DataBase Reference]
95635-56-6(CAS DataBase Reference) |
| Safety Data | Back Directory | [Safety Statements ]
S22:Do not breathe dust .
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
3
| [RTECS ]
TK7845370 | [HS Code ]
29335990 |
| Hazard Information | Back Directory | [Description]
Ranolazine is a piperazine derivative with cardioprotective activity.1,2,3,4 It reduces the late sodium current (INa) in mouse myocytes expressing the long QT syndrome 3 mutant sodium channel DKPQ, ventricular myocytes isolated from a canine model of heart failure, guinea pig ventricular myocytes exposed to hydrogen peroxide or anemone toxin-II, and HEK293 cells expressing human Nav1.5 channels (IC50s = 5.9-15 μM) as well as the late potassium current (IKr) in canine ventricular myocytes and HEK293 cells (IC50s = 11.5 and 14.4 μM, respectively).1,2 Ranolazine also inhibits radioligand binding to α1-, β1-, and β2-adrenergic receptors (Kis = 8.2-19.5, 1.4-8.6, and 0.5-14.8 μM, respectively).2 In vivo, ranolazine (480 μg/kg per min) reduces clofilium-induced prolongation of the QTc interval and Torsade de Pointes (TdP) in rabbits.3 Ranolazine also reduces interstitial collagen deposition as well as atrial natriuretic peptide (ANP; Item Nos. 24539 | 24276), connective tissue growth factor (CTGF), brain natriuretic peptide (BNP; Item No. 24541), and matrix metalloproteinase-2 (MMP-2) mRNA levels, and prevents left ventricular dilation in a mouse model of cardiotoxicity induced by doxorubicin (Item No. 15007).4 | [Chemical Properties]
White Crystalline Powder | [Uses]
treatment of angina and congestive heart failure | [Uses]
Anti-ischemic agent which modulates myocardial metabolism. Antianginal | [Uses]
Ranolazine Dihydrochloride is an anti-ischemic agent which modulates myocardial metabolism. Antianginal. | [Biological Activity]
Antianginal agent with antiarrhythmic properties that acts as a partial fatty acid oxidation inhibitor. Activates pyruvate dehydrogenase in ischemic myocytes to promote glucose oxidation, switching substrate utilization from fatty acids to glucose. Also shown to inhibit late I Na and I Kr currents. | [Biochem/physiol Actions]
Ranolazine is a derivative of anti-ischemic piperazine and acts as sodium (Na+)-current inhibitor. It has the potential to treat diastolic heart failure and helps in ameliorating myocardial diastolic function. | [storage]
Desiccate at RT | [References]
[1] J C SHRYOCK L B. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium[J]. British Journal of Pharmacology, 2009, 153 6: 1128-1132. DOI: 10.1038/sj.bjp.0707522
[2] RICHARD L VERRIER. Mechanisms of ranolazine’s dual protection against atrial and ventricular fibrillation.[J]. Europace, 2013, 15 3: 317-324. DOI: 10.1093/europace/eus380
[3] WEI-QUN WANG. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.[J]. Journal of Pharmacology and Experimental Therapeutics, 2008, 325 3: 875-881. DOI: 10.1124/jpet.108.137729
[4] CARLO G. TOCCHETTI. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction[J]. European Journal of Heart Failure, 2014, 16 4: 358-366. DOI: 10.1002/ejhf.50 |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
|